Sanofi set off an uproar in the Philippines with its 2017 disclosure that dengue shot Dengvaxia can cause more serious infections in previously uninfected people. Now, after investigations and demands for refunds, the country’s FDA permanently revoked Dengvaxia’s marketing license. More:
read moreA CDMO that has made a habit of snapping up Big Pharma’s discarded manufacturing plants has put a former AstraZeneca plant into bankruptcy. More: Former AstraZeneca UK plant back up for sale, putting 270 jobs at risk Source: fierce
read moreInvestors have been frustrated with Allergan’s reluctance to split up its chairman and CEO roles—particularly activist investor David Tepper. Now, the drugmaker says it supports an investor resolution to split the roles. The catch? It’ll hold off until current chief
read moreActivist hedge fund Starboard Value has reportedly hired a proxy solicitor to survey the level of support for the $74 billion Celgene buy. Starboard’s interest may be in thwarting the deal by trying to find another buyer for BMS, some
read moreEager to pump up its pipeline and under pressure from investors, Bayer has decided to carve a piece out of Eli Lilly’s recently acquired Loxo Oncology. It’s taking full control of its Loxo-partnered Vitrakvi, the first drug to get an
read moreGyroscope Therapeutics has announced that the first patient has been dosed in its Phase I/II FOCUS study for dry age-related macular degeneration (AMD). More: First patient dosed in Gyroscope Therapeutics’ AMD study Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals